ReviewOncology and therapy2026

Beyond the BCG Paradox: Biological Rationale and Clinical Evidence for Combining Intravesical BCG with Immune Checkpoint Inhibitors in High-Risk Non-muscle-Invasive Bladder Cancer.

Michele Musone et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.